Skip to NavigationSkip to content

Eli Lilly's heart drug underwhelms with REWIND trial

Published on 11/06/19 at 11:28am

Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.

The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.

While Lilly’s drug was effective in reducing major cardiovascular events the drug failed to meet the expectations of investors. According to MarketWatch Cowen analysts said investors had expected at least 20% risk reduction.

Shares in the Indianapolis-based firm fell by 2.4% in premarket trading.  

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches